This trial is evaluating whether 18F-fluciclovine will improve 1 primary outcome and 3 secondary outcomes in patients with Urinary Bladder Cancer. Measurement will happen over the course of 2 years.
This trial requires 16 total participants across 1 different treatment group
This trial involves a single treatment. 18F-fluciclovine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
"The cause of carcinoma, TCC remains a mystery, though it is probably related to certain environmental elements and possibly other factors. It is probable that carcinoma, TCC is caused by complex interaction of genetic, environmental, hormonal and other factors." - Anonymous Online Contributor
"The incidence of this malignancy, unlike cervical malignancies among both men and women, will fall in the next forty years, a decline that could offset any increase in incidence for cervical malignancies among white women." - Anonymous Online Contributor
"Transitional cell carcinoma of the bladder generally cannot be cured due to a high recurrent rate and a low cure rate. The highest cure rate has been reported for TCC of the bladder confined to the bladder." - Anonymous Online Contributor
"Symptoms of endometriosis include pelvic pain, bleeding from the vagina, infertility and abnormal bleeding or spotting after menopause.\n\nSymptoms of cancer of the breast\nNote: Symptoms of breast cancer vary depending on the location of the primary tumor. Lymph nodes may become swollen with adhesions and in the axillary area may become tender and hard to palpate. Some breast cancers may also cause lymphedema. \n\nSymptoms of cancer of the pancreas\nNote: Symptoms of pancreatic cancer vary depending on the location of the primary tumor. Most of the symptoms appear gradual over months to years. Lymph nodes around or in the abdomen may become enlarged." - Anonymous Online Contributor
"Carcinoma, transitional cell of the bladder is the third most common bladder tumor (0.14% of the population will have had such a tumor). In more than half of cases, the tumor is detected by the symptoms of hematuria, frequent urination or pain over the course of weeks or months. It usually progresses slowly and metastasizes by way of the vascular system only to a limited and usually peripheral part of the urinary bladder. The prognosis is determined by the stage of the cancer, the type of treatment given, the underlying type of bladder cancer (transitional cell carcinoma) and the individual tumor markers. The majority of patients treated with surgery will have a five-year survival of 80-95%." - Anonymous Online Contributor
"There are many forms of treatment, including surgery, chemotherapy, radiation therapy, targeted therapy, and chemoradiation. These treatments are tailored to the condition of the patient, however, most of them have the same goal—to prolong life." - Anonymous Online Contributor
"The speed of carcinoma, transitional cell spread appears to be related to the aggressiveness of carcinoma, transitional cell cancer as well as the amount of spread of carcinoma, transitional cell cancer at the time of initial diagnosis." - Anonymous Online Contributor
"There are not enough [cancer trials for transitional cell and bladder cancer] (https://www.hss.edu/ConditionList/BladderCarcinoma%20Transitional%20Cell%20Kidney%20Treatment_Cancer_Trial.aspx). Patients need to be informed that some therapeutic options are ineffective for either bladder or transitional cell cancers as only small study samples remain in clinical trials. In addition, there are no data to be based on. Power to help you find trials tailored to your treatment." - Anonymous Online Contributor
"The common side effects during treatment with (18)F-FDG are similar to those produced by other 18F-labeled FDG analogues, namely nausea, fatigue, malaise, loss of appetite, headache, vomiting, urinary incontinence, and loss of appetite. The number and severity of adverse effects is higher in patients treated with (18)F-FDG compared to patients treated with (11)C-methionine-dextroamphetamine (MDR2-INVIBEM) in a prospective trial of MDR2-defined MDR2-positive patients." - Anonymous Online Contributor
"18F-FL will be a useful agent to use with patients who have received prior radiotherapy to evaluate disease recurrence, and in future it may prove to be more effective for imaging purposes than its sibling, 18F-FDG." - Anonymous Online Contributor
"F-18FLV has been reported to be useful for the detection of tumor and inflammation in various areas. It is also used as a tracer in the study of the brain, prostate, esophagus, kidney, and liver." - Anonymous Online Contributor
"(18)F)F-fluciclovine PET is a rapid and reliable tool for functional imaging of the [F]-labeled adhesion molecule MUC18, known to overexpress at high levels in bladder cancer, at tumors that bear overexpression of MUC18, and within a subset of bladder tumors with minimal staining for MUC18. A potential role, as an indicator of tissue aggressiveness, or as a biomarker for evaluating the effects of anticancer therapeutics or therapies blocking MUC18 may warrant further study." - Anonymous Online Contributor